文献速递垂体与肾上腺疾病

林奇综合征患者中的促肾上腺皮质激素垂体癌及全国性林奇综合征队列中的垂体肿瘤

Corticotroph Pituitary Carcinoma in a Patient With Lynch Syndrome (LS) and Pituitary Tumors in a Nationwide LS Cohort.
PubMed 文献 · J Clin Endocrinol Metab · 2017-01-01

本文报告一名51岁林奇综合征(MSH2突变)男性患者,表现为严重库欣病和局部侵袭性垂体瘤,16个月后进展为伴广泛肝转移的垂体癌。作者在瑞典全国910例林奇综合征患者中检索垂体瘤,共发现3例肿瘤(预期1例),并提出在侵袭性垂体瘤评估中主动询问林奇综合征家族史。

要点

  • 林奇综合征(MSH2突变)患者可发生促肾上腺皮质激素垂体癌并出现肝转移。
  • 瑞典全国910例林奇综合征患者中检出3例临床相关垂体瘤,预期为1例。
  • 作者建议在侵袭性垂体瘤的评估中主动询问林奇综合征家族史。

核心结论

  • DNA错配修复基因的胚系突变可能参与垂体瘤的发生和/或临床病程。
  • 作者建议在侵袭性垂体瘤的评估中主动询问林奇综合征家族史。

研究设计与样本

  • 病例报告:一名51岁林奇综合征(MSH2突变)男性患者,有结肠癌病史。
  • 全国性研究:在瑞典国家患者登记中检索林奇综合征患者的垂体瘤诊断,覆盖瑞典所有已知的910例林奇综合征患者。

主要发现

  • 病例:患者表现为严重库欣病和局部侵袭性垂体瘤,肿瘤携带与患者胚系突变一致的突变并显示错配修复功能缺陷。
  • 病例:16个月后肿瘤发展为癌并出现广泛肝转移。
  • 全国性研究:910例林奇综合征患者中另发现2例临床相关垂体瘤,分别为侵袭性无分泌功能大腺瘤和微泌乳素瘤,共3例肿瘤 vs 预期1例。

临床怎么用

  • 作者建议在侵袭性垂体瘤的评估中主动询问林奇综合征家族史。
  • 作者指出携带错配修复突变的肿瘤对免疫检查点抑制剂治疗敏感。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Lynch syndrome (LS) is a cancer-predisposing syndrome caused by germline mutations in genes involved in DNA mismatch repair (MMR). Patients are at high risk for several types of cancer, but pituitary tumors have not previously been reported. CASE: A 51-year-old man with LS (MSH2 mutation) and a history of colon carcinoma presented with severe Cushing disease and a locally aggressive pituitary tumor. The tumor harbored a mutation consistent with the patient's germline mutation and displayed defect MMR function. Sixteen months later, the tumor had developed into a carcinoma with widespread liver metastases. The patient prompted us to perform a nationwide study in LS. NATIONWIDE STUDY: A diagnosis consistent with a pituitary tumor was sought for in the Swedish National Patient Registry. In 910 patients with LS, representing all known cases in Sweden, another two clinically relevant pituitary tumors were found: an invasive nonsecreting macroadenoma and a microprolactinoma (i.e., in total three tumors vs. one expected). CONCLUSION: Germline mutations in MMR genes may contribute to the development and/or the clinical course of pituitary tumors. Because tumors with MMR mutations are susceptible to treatment with immune checkpoint inhibitors, we suggest to actively ask for a family history of LS in the workup of patients with aggressive pituitary tumors.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Bengtsson D, Joost P, Aravidis C, et al. Corticotroph Pituitary Carcinoma in a Patient With Lynch Syndrome (LS) and Pituitary Tumors in a Nationwide LS Cohort. J Clin Endocrinol Metab. 2017. PMID: 28938458. doi:10.1210/jc.2017-01401

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。